- Home
- PMN vs APM Comparison
PMN vs APM Comparison
Compare PMN & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- APM
- Stock Information
- Founded
- PMN 2004
- APM 2010
- Country
- PMN Canada
- APM United Kingdom
- Employees
- PMN N/A
- APM N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- PMN Health Care
- APM Health Care
- Exchange
- PMN Nasdaq
- APM Nasdaq
- Market Cap
- PMN 22.3M
- APM 18.9M
- IPO Year
- PMN N/A
- APM 2018
- Fundamental
- Price
- PMN $0.46
- APM $1.80
- Analyst Decision
- PMN Strong Buy
- APM
- Analyst Count
- PMN 3
- APM 0
- Target Price
- PMN $4.33
- APM N/A
- AVG Volume (30 Days)
- PMN 3.1M
- APM 20.5M
- Earning Date
- PMN 11-13-2025
- APM 04-30-2025
- Dividend Yield
- PMN N/A
- APM N/A
- EPS Growth
- PMN N/A
- APM N/A
- EPS
- PMN N/A
- APM N/A
- Revenue
- PMN N/A
- APM N/A
- Revenue This Year
- PMN N/A
- APM N/A
- Revenue Next Year
- PMN N/A
- APM N/A
- P/E Ratio
- PMN N/A
- APM N/A
- Revenue Growth
- PMN N/A
- APM N/A
- 52 Week Low
- PMN $0.38
- APM $0.46
- 52 Week High
- PMN $1.59
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- PMN 43.27
- APM 49.26
- Support Level
- PMN $0.39
- APM $1.64
- Resistance Level
- PMN $0.45
- APM $2.02
- Average True Range (ATR)
- PMN 0.04
- APM 0.16
- MACD
- PMN 0.00
- APM -0.04
- Stochastic Oscillator
- PMN 38.24
- APM 21.05
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.